Market News AIOpen the app

BNTC stock news · Benitec Biopharma

Stories about Benitec Biopharma (BNTC) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BNTC

Follow Benitec Biopharma (BNTC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BNTC
Free on the App Store and Google Play, or on the web.
  1. Nov 13, 2026, 9:18 AM ET · Market

    Benitec Biopharma lost $12.9 million last quarter and shared updates on its BB-301 gene therapy, showing a 100% response rate.

    Good for BNTC

    Benitec reported a $12.9 million quarterly loss, up from $9.0 million, and $176.5 million in cash. BB-301 had a 100% responder rate across 2 groups, making the update favorable.

  2. Nov 13, 2026, 8:04 AM ET · Market

    Benitec Biopharma shared its first quarter results and reported that its BB-301 treatment had a 100% success rate in early tests.

    Good for BNTC

    Benitec reported a 100% response among 9 patients in its BB-301 study and held about $176 million in cash. These results support a positive read, though the study remains small.

  3. Sep 30, 2026, 4:16 PM ET · Market

    Benitec Biopharma Inc. has a new accounting firm, Ernst & Young LLP, for the next few years.

    Neutral

    Benitec completed the appointment of EY as its accountant for fiscal 2027. The filing gives no new information about its business, so the company outlook is unchanged.

  4. Sep 24, 2026, 4:56 PM ET · Market

    Benitec Biopharma Inc. has switched its accountant from Baker Tilly to Ernst & Young.

    Neutral

    Benitec replaced its auditor with EY and said a prior control weakness was fixed; this filing does not change the company's view today.